Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-T11 study for newly diagnosed T-cell acute lymphoblastic leukemia in children, adolescents, and young adults
jRCTs041180145Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nelarabine, asparaginase escherichia coli, prednisolone and dexamethasone in t-cell acute lymphoblastic leukemia (T-ALL) (4 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: 3-year event-free survival and MRD disappearance in the very high-risk randomized cohort. Started Dec 2011; status: completed.
02
Drugs
nelarabineasparaginase escherichia coliprednisolonedexamethasone
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on jRCTs041180145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180145.